Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome

Frank González, Chang Ling Sia, Frank Z. Stanczyk, Hilary E. Blair, Michelle E. Krupa

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We determined the effect of chronic androgen suppression on inflammation in women with polycystic ovary syndrome (PCOS) compared to weight-matched controls. We performed a pilot project using samples from previous prospective, controlled studies. Nine women with PCOS (5 obese, 4 lean) and 9 ovulatory controls (5 obese, 4 lean) participated in the study. Androgens, C-reactive protein (CRP), interleukin-6 (IL-6), free fatty acids (FFA) and body weight were measured before and after 3 and 6 months of gonadotropin-releasing hormone (GnRH) agonist administration. GnRH agonist treatment decreased estradiol, testosterone and androstenedione to similar levels in all subjects. CRP and IL-6 increased in obese women with PCOS, was unaltered in lean women with PCOS and obese controls, and decreased in lean controls after 6 months of treatment. FFA decreased and body weight increased in obese women with PCOS, but did not change significantly in lean women with PCOS and in either control group after 6 months of treatment. The testosterone reduction was related to increases in weight and IL-6. The fall in FFA was related to the rise in CRP. The increases in weight and IL-6 were related to the rise in CRP. We propose that hyperandrogenism in PCOS may exert an anti-inflammatory effect when obesity is present, but may not promote inflammation in the disorder; and that circulating androgens have a pleiotropic effect on inflammation depending on the combination of PCOS and weight status in a given individual.

Original languageEnglish
Pages (from-to)726-735
Number of pages10
JournalEndocrine
Volume42
Issue number3
DOIs
StatePublished - Dec 2012

Fingerprint

Hyperandrogenism
Polycystic Ovary Syndrome
Anti-Inflammatory Agents
C-Reactive Protein
Interleukin-6
Nonesterified Fatty Acids
Androgens
Weights and Measures
Inflammation
Gonadotropin-Releasing Hormone
Testosterone
Body Weight
Androstenedione
Estradiol
Therapeutics
Obesity
Prospective Studies
Control Groups

Keywords

  • Adiposity
  • Androgens
  • Inflammation
  • Lypolysis

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

González, F., Sia, C. L., Stanczyk, F. Z., Blair, H. E., & Krupa, M. E. (2012). Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome. Endocrine, 42(3), 726-735. https://doi.org/10.1007/s12020-012-9728-6

Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome. / González, Frank; Sia, Chang Ling; Stanczyk, Frank Z.; Blair, Hilary E.; Krupa, Michelle E.

In: Endocrine, Vol. 42, No. 3, 12.2012, p. 726-735.

Research output: Contribution to journalArticle

González, F, Sia, CL, Stanczyk, FZ, Blair, HE & Krupa, ME 2012, 'Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome', Endocrine, vol. 42, no. 3, pp. 726-735. https://doi.org/10.1007/s12020-012-9728-6
González, Frank ; Sia, Chang Ling ; Stanczyk, Frank Z. ; Blair, Hilary E. ; Krupa, Michelle E. / Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome. In: Endocrine. 2012 ; Vol. 42, No. 3. pp. 726-735.
@article{2fe3d31ef29540fc8e6add7e2b1cf798,
title = "Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome",
abstract = "We determined the effect of chronic androgen suppression on inflammation in women with polycystic ovary syndrome (PCOS) compared to weight-matched controls. We performed a pilot project using samples from previous prospective, controlled studies. Nine women with PCOS (5 obese, 4 lean) and 9 ovulatory controls (5 obese, 4 lean) participated in the study. Androgens, C-reactive protein (CRP), interleukin-6 (IL-6), free fatty acids (FFA) and body weight were measured before and after 3 and 6 months of gonadotropin-releasing hormone (GnRH) agonist administration. GnRH agonist treatment decreased estradiol, testosterone and androstenedione to similar levels in all subjects. CRP and IL-6 increased in obese women with PCOS, was unaltered in lean women with PCOS and obese controls, and decreased in lean controls after 6 months of treatment. FFA decreased and body weight increased in obese women with PCOS, but did not change significantly in lean women with PCOS and in either control group after 6 months of treatment. The testosterone reduction was related to increases in weight and IL-6. The fall in FFA was related to the rise in CRP. The increases in weight and IL-6 were related to the rise in CRP. We propose that hyperandrogenism in PCOS may exert an anti-inflammatory effect when obesity is present, but may not promote inflammation in the disorder; and that circulating androgens have a pleiotropic effect on inflammation depending on the combination of PCOS and weight status in a given individual.",
keywords = "Adiposity, Androgens, Inflammation, Lypolysis",
author = "Frank Gonz{\'a}lez and Sia, {Chang Ling} and Stanczyk, {Frank Z.} and Blair, {Hilary E.} and Krupa, {Michelle E.}",
year = "2012",
month = "12",
doi = "10.1007/s12020-012-9728-6",
language = "English",
volume = "42",
pages = "726--735",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome

AU - González, Frank

AU - Sia, Chang Ling

AU - Stanczyk, Frank Z.

AU - Blair, Hilary E.

AU - Krupa, Michelle E.

PY - 2012/12

Y1 - 2012/12

N2 - We determined the effect of chronic androgen suppression on inflammation in women with polycystic ovary syndrome (PCOS) compared to weight-matched controls. We performed a pilot project using samples from previous prospective, controlled studies. Nine women with PCOS (5 obese, 4 lean) and 9 ovulatory controls (5 obese, 4 lean) participated in the study. Androgens, C-reactive protein (CRP), interleukin-6 (IL-6), free fatty acids (FFA) and body weight were measured before and after 3 and 6 months of gonadotropin-releasing hormone (GnRH) agonist administration. GnRH agonist treatment decreased estradiol, testosterone and androstenedione to similar levels in all subjects. CRP and IL-6 increased in obese women with PCOS, was unaltered in lean women with PCOS and obese controls, and decreased in lean controls after 6 months of treatment. FFA decreased and body weight increased in obese women with PCOS, but did not change significantly in lean women with PCOS and in either control group after 6 months of treatment. The testosterone reduction was related to increases in weight and IL-6. The fall in FFA was related to the rise in CRP. The increases in weight and IL-6 were related to the rise in CRP. We propose that hyperandrogenism in PCOS may exert an anti-inflammatory effect when obesity is present, but may not promote inflammation in the disorder; and that circulating androgens have a pleiotropic effect on inflammation depending on the combination of PCOS and weight status in a given individual.

AB - We determined the effect of chronic androgen suppression on inflammation in women with polycystic ovary syndrome (PCOS) compared to weight-matched controls. We performed a pilot project using samples from previous prospective, controlled studies. Nine women with PCOS (5 obese, 4 lean) and 9 ovulatory controls (5 obese, 4 lean) participated in the study. Androgens, C-reactive protein (CRP), interleukin-6 (IL-6), free fatty acids (FFA) and body weight were measured before and after 3 and 6 months of gonadotropin-releasing hormone (GnRH) agonist administration. GnRH agonist treatment decreased estradiol, testosterone and androstenedione to similar levels in all subjects. CRP and IL-6 increased in obese women with PCOS, was unaltered in lean women with PCOS and obese controls, and decreased in lean controls after 6 months of treatment. FFA decreased and body weight increased in obese women with PCOS, but did not change significantly in lean women with PCOS and in either control group after 6 months of treatment. The testosterone reduction was related to increases in weight and IL-6. The fall in FFA was related to the rise in CRP. The increases in weight and IL-6 were related to the rise in CRP. We propose that hyperandrogenism in PCOS may exert an anti-inflammatory effect when obesity is present, but may not promote inflammation in the disorder; and that circulating androgens have a pleiotropic effect on inflammation depending on the combination of PCOS and weight status in a given individual.

KW - Adiposity

KW - Androgens

KW - Inflammation

KW - Lypolysis

UR - http://www.scopus.com/inward/record.url?scp=84878231156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878231156&partnerID=8YFLogxK

U2 - 10.1007/s12020-012-9728-6

DO - 10.1007/s12020-012-9728-6

M3 - Article

C2 - 22752961

AN - SCOPUS:84878231156

VL - 42

SP - 726

EP - 735

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 3

ER -